Myriad Genetics Inc (NASDAQ:MYGN)
| 19.47 Delayed Data As of 4:00pm ET |  +1.26 / +6.92%Today’s Change | 16.02 Today|||52-Week Range 33.18 | -29.46% Year-to-Date |
Latest MYGN News | Press Releases
| Here's Why Investors Should Hold Myriad Genetics (MYGN) Now Sep 26 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 18.21 |
| Today’s open | 18.52 |
| Day’s range | 18.52 - 19.63 |
| Volume | 32,940 |
| Average volume (3 months) | 523,535 |
| Market cap | $1.5B |
Data as of 4:00pm ET, 09/28/2022
Growth & Valuation
| Earnings growth (last year) | +87.01% |
| Earnings growth (this year) | -362.50% |
| Earnings growth (next 5 years) | +4.00% |
| Revenue growth (last year) | +8.14% |
| P/E ratio | NM |
| Price/Sales | 3.12 |
| Price/Book | 1.55 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| VIVOMeridian Bioscience ... | +0.25 | +0.79% |
| CLDXCelldex Therapeutics... | +1.01 | +3.63% |
| VCYTVeracyte Inc | +0.44 | +2.60% |
| ---- |
Data as of 4:00pm ET, 09/28/2022
Financials
| Next reporting date | November 1, 2022 |
| EPS forecast (this quarter) | -$0.06 |
| Annual revenue (last year) | $690.6M |
| Annual profit (last year) | -$27.2M |
| Net profit margin | -3.94% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Salt Lake City, Utah |
Forecasts
